Across TCGA pan-cancer cohorts, SNORA66 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SNORA66’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where SNORA66 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA66 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.
COAD, READ, and LUSC are the cancer types where SNORA66 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA66 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.